Xbrane Biopharma AB (XBRANE)

Currency in SEK
11.80
+1.15(+10.80%)
Real-time Data·
XBRANE is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
10.4012.20
52 wk Range
5.4220.00
Key Statistics
Prev. Close
10.65
Open
10.6
Day's Range
10.4-12.2
52 wk Range
5.42-20
Volume
145.78K
Average Volume (3m)
94.91K
1-Year Change
17.2962%
Book Value / Share
25.58
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
XBRANE Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Valuation implies a strong free cash flow yield

Xbrane Biopharma AB News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Xbrane Biopharma AB Earnings Call Summary for Q2/2026

  • Q2 revenue hit SEK 46.8M as Ximluci shipments to STADA resumed; adjusted gross margin was 26% excluding one-time items vs. 5% reported.
  • Company expects continued Ximluci shipments through Q3-Q4 2026 and targets ~50% production cost reduction starting mid-2027.
  • U.S. BLA for Ximluci resubmitted in April with October 2026 PDUFA date; management says no upfront payment expected from Valorum partner.
  • Pipeline advances with Xdivane BLA filing targeted for 2027 and Xdarzane co-development deal with JOINN Biologics limiting capital needs.
  • Cash position of SEK 15M plus SEK 175M inventory deemed sufficient for operations; operating cash flow negative SEK 4.8M in Q2.
Last Updated: 2026-07-17, 03:34 a/m
Read Full Transcript

Earnings

Latest Release
Oct 30, 2026
EPS / Forecast
-0.56 / -0.51
Revenue / Forecast
55M / 24M
EPS Revisions
Last 90 days

XBRANE Income Statement

Compare XBRANE to Peers and Sector

Metrics to compare
XBRANE
Peers
Sector
Relationship
P/E Ratio
−3.6x−0.5x−0.2x
PEG Ratio
0.000.400.00
Price/Book
0.4x2.9x2.6x
Price / LTM Sales
1.8x5.7x2.7x
Upside (Analyst Target)
47.8%355.9%66.0%
Fair Value Upside
Unlock27.4%10.8%Unlock

Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. It offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults. The company also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; and Xdarzane, a daratumumab biosimilar targeting CD38 for the treatment of multiple myeloma. The company has a strategic partnership with JOINN Biologics US Inc. to provide customized development services for Xdarzane, Xbrane´s biosimilar candidate referencing Darzalex. The company was incorporated in 2008 and is headquartered in Solna, Sweden.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
0.000.00%0.00
Other Institutional Investors
2.13M10.35%22.71M
Public Companies & Retail Investors
18.47M89.65%196.74M
Total
20.61M100.00%219.45M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Six Rays Pte. Limited10.35%2,132,26722,709

FAQ

What Is the Xbrane Biopharma (XBRANE) Stock Price Today?

The Xbrane Biopharma stock price today is 11.80 SEK.

What Stock Exchange Does Xbrane Biopharma Trade On?

Xbrane Biopharma is listed and trades on the Stockholm Stock Exchange.

What Is the Stock Symbol for Xbrane Biopharma?

The stock symbol for Xbrane Biopharma is "XBRANE."

What Is the Xbrane Biopharma Market Cap?

As of today, Xbrane Biopharma market cap is 243.14M SEK.

What Is Xbrane Biopharma's Earnings Per Share (TTM)?

The Xbrane Biopharma EPS (TTM) is -3.00.

When Is the Next Xbrane Biopharma Earnings Date?

Xbrane Biopharma will release its next earnings report on Feb 19, 2027.

From a Technical Analysis Perspective, Is XBRANE a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Xbrane Biopharma Stock Split?

Xbrane Biopharma has split 3 times.

How Many Employees Does Xbrane Biopharma Have?

Xbrane Biopharma has 28 employees.

What is the current trading status of Xbrane Biopharma (XBRANE)?

As of Nov 17, 2026, Xbrane Biopharma (XBRANE) is trading at a price of 11.80 SEK, with a previous close of 10.65 SEK. The stock has fluctuated within a day range of 10.40 SEK to 12.20 SEK, while its 52-week range spans from 5.42 SEK to 20.00 SEK.

What Is Xbrane Biopharma (XBRANE) Price Target According to Analysts?

The average 12-month price target for Xbrane Biopharma is 17.00 SEK, with a high estimate of 17 SEK and a low estimate of 17 SEK. 0 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +44.07% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.